The upfront consideration for the transaction is $12 million, payable at closing. In addition, Strides will make royalty payments to Sandoz based on a percentage of net sales of distribution products. Shares of Strides Pharma Science Ltd ended at ₹876.55, down by ₹14.40, or 1.62%, on the BSE today, March 17.
